RxDoctor Payments Data

Mustafa Abas, MD

Pulmonary Disease · Chardon, OHNPI 1720392988

Payments from drug & device makers

$521in general payments, 2019–2025

Across 26 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$94
  • Insmed, Inc.$85
  • Sanofi$70
  • Sanofi-aventis U.S. LLC$57
  • Baxter Healthcare$32
  • Verona Pharma, Inc.$31
  • plus $151 from 9 others

What the payments were for

  • Food & beverage$44886%
  • Education$7414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$521 in reported general payments places this provider in the 30th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$105,279
Medicare patients
427
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter222$179,878
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr152$81,650
NucalaMepolizumab17$62,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$49,289
Breo ElliptaFluticasone/Vilanterol84$44,772
Stiolto RespimatTiotropium Br/Olodaterol Hcl49$30,831
Spiriva HandihalerTiotropium Bromide39$23,907
Advair HfaFluticasone Propion/Salmeterol31$16,239
Incruse ElliptaUmeclidinium Bromide26$13,327
SymbicortBudesonide/Formoterol Fumarate40$10,749
Spiriva RespimatTiotropium Bromide12$8,052
Albuterol Sulfate HfaAlbuterol Sulfate289$6,292
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$6,270
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,979
Fluticasone-SalmeterolFluticasone Propion/Salmeterol82$5,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$94$381,852501 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$14$66,018124 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$14$38,88361 claims
MerckDulera$19$4,69212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →